Sun Pharmaceutical Industries Ltd. share price target

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 47 manufacturing facilities spread across 6 continents, R&D; centers across the globe and a multi-cultural workforce comprising over 50 nationalities. In India, it enjoys leadership across 13 different classes of doctors with 30 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 14 world class API...

For 4QFY2016, Sun Pharmaceuticals Industries (Sun Pharma) posted results marginally lower than our expectations. Sales for the quarter, at Rs7,414cr (V/s Rs7,700cr estimated) grew 20.7% yoy. On the operating front, the company posted an OPM of 31.0% V/s 14.3% in 4QFY2015 and V/s our expectation of 34.9%. Thus, the net profit came in at Rs..

Background: Sun Pharma is among the largest players in the domestic formulations market and the most profitable one with Indian and US as its focus markets. It makes and markets specialty medicines and APIs for chronic therapy areas such as cardiology, psychiatry, neurology, etc. Strength in high-growth chronic segments has propelled Sun to sixth rank in the domestic formulations market, with consistent outperformance to market and large-sized peers. Sun has forayed into regulated markets by acquiring majority stake in Caraco Pharma and has strengthened its presence in US by recent acquisition of Taro. With Taro's acquisition, Sun has become the largest...

8 Given the +ve volume surprise in gGleevec and strong Taro performance, SUNP's Q4 earnings is 19% below our estimates. This implies weaker operating performance by SUNP'sbasebusinessandrelativelyweakerinventorypushingGleevec....

ICICI Securities Ltd | Retail Equity Research Revenues grew 7.8% QoQ to | 7634 crore (I-direct estimate: | 7605 crore) due to 22.2% QoQ increase in US sales to | 3910 crore (Idirect estimate: | 3642 crore). US sales growth was due to gGleevec...

A strong quarter; Management provides modest FY17 top line guidance Sun Pharma's (SUNP) reported sales of INR76.3bn (in line with our est.), along with higher than expected EBITDA margin of 33% (vs. our est. of 32.4%) and PAT of...

9 Taro having a cash warchest of >US$ 1.2bn will look for an acquisition of specialty pharmaassetsintheUS.However,itindicatestoremaindisciplinedindeployingcash. 9 Taro has filed 10 ANDA in FY16 and expects it to maintain this runrate of filing for...

Taro (a subsidiary of Sun Pharma) announced today that it has ceased commercial sales and related promotional activities for Keveyis We had estimated revenue of ~USD40m in FY17 from Keveyis (0.8% of sales and...

SUNP launched gGleevec in the US under exclusivity at only 10% discount to the branded productsapositivesurprisetoourestimateof30%.SUNP'spatentsettlementpactwith innovator (Novartis) seems a winwin for both as they are not indulging in the normal...

Background: Sun Pharma is among the largest players in the domestic formulations market and the most profitable one with Indian and US as its focus markets. It makes and markets specialty medicines and APIs for chronic therapy areas such as cardiology, psychiatry, neurology, etc. Strength in high-growth chronic segments has propelled Sun to sixth rank in the domestic formulations market, with consistent outperformance to market and large-sized peers. Sun has forayed into regulated markets by acquiring majority stake in Caraco Pharma and has strengthened its presence in US by recent acquisition of Taro. With Taro's acquisition, Sun has become the largest...